María José
Larráyoz Ilundáin
Clínico Asociado
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Marqués de Valdecilla (5)
2024
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
-
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
Haematologica
2018
-
Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia
Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73
2014
-
Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm
Leukemia, Vol. 28, Núm. 4, pp. 823-829
2003
-
Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response
Haematologica, Vol. 88, Núm. 12, pp. 1425-1426